Eton Pharmaceuticals Secured Rights for Seizure Film
A new licensing agreement for the seizure-cluster medication LIBERVANT sets the stage for a U.S. launch in April 2027.
Updated on Oct. 14, 2026 in Alzheimer’s
Live Poll
Do you believe exclusive pharmaceutical licensing agreements typically result in better access to new treatments?
Eton Pharmaceuticals and Aquestive Therapeutics have entered into an exclusive licensing and supply agreement for LIBERVANT, a diazepam buccal film used for seizure clusters. The product, which aims to provide an alternative to existing nasal and rectal rescue treatments, is expected to become commercially available in the United States in April 2027.
Why it matters
This agreement expands the availability of non-nasal and non-rectal rescue options for epilepsy patients managing seizure clusters. It positions the drug to compete within a U.S. seizure rescue market that exceeds $450 million annually.
Market research involving 101 patients indicated that 71% prefer film delivery for seizure rescue over nasal sprays, while 76% expressed concern about medication accessibility away from home. These findings support the planned rollout of the film-based treatment, though the final label expansion for pediatric patients remains under review.
The players
Eton Pharmaceuticals
A pharmaceutical company focused on the development and commercialization of treatments for rare diseases.
Aquestive Therapeutics
A pharmaceutical company specializing in the development of orally administered medicines.
The details
LIBERVANT is a diazepam buccal film designed for use during seizure clusters in patients with epilepsy. The drug works as a rescue medication by being absorbed through the cheek lining, offering an alternative to common nasal and rectal administration methods. Eton Pharmaceuticals plans to support the rollout through a dedicated neurology team that will focus on physician education and patient advocacy programs.
Timeline
November 2016: FDA granted Orphan Drug Designation to LIBERVANT.
January 10, 2027: Expiration of VALTOCO orphan drug exclusivity.
March 29, 2027: PDUFA target action date for the pending New Drug Application.
April 2027: Anticipated commercial availability of LIBERVANT.
2038: Expiration of issued patent protection for LIBERVANT.
Health Landscape
The introduction of LIBERVANT follows the expiration of VALTOCO orphan drug exclusivity, marking a shift in the availability of seizure rescue options. This development reflects a broader industry trend toward diversifying delivery mechanisms for patients with epilepsy.
If you or a family member manage seizure clusters, it may be helpful to track future updates regarding the availability of buccal film delivery options. Discuss with your neurologist whether current rescue medication plans align with your lifestyle needs and concerns about administration away from home.
The takeaway
The addition of new rescue delivery methods provides more options for patients requiring portability for seizure management. When discussing your emergency action plan with your physician, inquire about the different delivery technologies currently available and those expected in the coming years.
What happens next
The FDA has set a PDUFA target action date of March 29, 2027, for the New Drug Application to expand the treatment label to include patients ages 6 to 11.
Further reading
For context on the latest developments in neurodegenerative care and access, visit our Alzheimer’s section.
Live Poll
Do you believe exclusive pharmaceutical licensing agreements typically result in better access to new treatments?
